Indicated for: cancer
Route of administration: infusion
Substance: trabectedin (antineoplastic agent)
ATC: L01CX01 (Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Other plant alkaloids and natural products)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Trabectedin is an antineoplastic agent used in the treatment of advanced soft tissue sarcomas and recurrent ovarian cancer. It is a compound derived from a natural product extracted from a marine organism, Ecteinascidia turbinata, and works by binding to DNA, inhibiting gene transcription, and inducing apoptosis in tumor cells.
Trabectedin is administered intravenously, usually in 3-week cycles, with the dose adjusted based on the patient's body weight and tolerability. It is often used in combination with pegylated liposomal doxorubicin for ovarian cancer treatment.
Common side effects include nausea, vomiting, fatigue, neutropenia, and elevated liver enzyme levels. In rare cases, severe adverse reactions such as rhabdomyolysis, liver failure, or serious infections may occur. Careful monitoring of hematological and liver parameters is essential during treatment.
Trabectedin is a valuable therapeutic option for patients with sarcomas and ovarian cancer, contributing to prolonged survival and improved quality of life.